Onkológia 4/2009

Pegylated liposomal doxorubicin in the treatment of recurent ovarian cancer

The combination of pactlitaxel and carboplatin is generally standard 1-line treatment of advanced ovarian cancer. Treatment of recurrent ovarian cancer is a serious problem and depends on several factors. Pegylated liposomal doxorubicin (PLD) single agent or in combination has its place in treatment of recurrent ovarian cancer. In platinum intermediately sensitive relaps the appropriate treatment is combination pegylated liposomal doxorubicin and platinum or monotherapy of pegylated liposomal doxorubicin. Pegylated liposomal doxorubicin also recommended as a second-line treatment option for women with platinum-resistant, platinum-refractory ovarian cancer and allergic to platinum based compounds.

Keywords: recurrent ovarian cancer, pegylated liposomal doxorubicin